Kinnate Biopharma GAAP EPS of -$0.70 misses by $0.10

Nov. 10, 2022 11:29 PM ETKinnate Biopharma Inc. (KNTE)By: Deepa Sarvaiya, SA News Editor
  • Kinnate Biopharma press release (NASDAQ:KNTE): Q3 GAAP EPS of -$0.70 misses by $0.10.
  • Cash and Cash Equivalents and Investments Position: As of September 30, 2022, the total of cash and cash equivalents and investments was $262.1 million, excluding cash from its China joint venture, Kinnjiu, and is expected to fund current operations into mid-2024

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.